DANBURY, Conn., Dec. 5 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq:
BIOD) today announced that it will issue its fourth quarter and fiscal year
2007 financial results on December 11, 2007. Following the issuance of its
financial results, Biodel's senior management team will host a conference
call to discuss the results.
December 11, 2007 Schedule:
After the market closes Q4 and fiscal year 2007 results will be
distributed by PR Newswire
4:20 p.m. EST To participate in the conference call, dial:
1-877-718-5104 (United States) or
4:30 p.m. EST Conference call begins
Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay 14 days following the event.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and two osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other then statements of historical facts, including statements
regarding our strategy, future operations, future financial position,
future revenues, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words "anticipates,"
"believes," "could," "estimates," "expects," "intends," "may," "plans,"
"potential," "predicts," "projects," "should," "will," "would" and similar
expressions are intended to identify forward-looking statements, although
not all forward-looking statements contain these identifying words. The
Company's forward-looking statements are subject to a number of known and
unknown risks and uncertainties that could cause actual results,
performance or achievements to differ materially from those described or
implied in the forward-looking statements, including, but not limited to,
our ability to secure FDA approval for our product candidates under Section
505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to
market, commercialize and achieve market acceptance for product candidates
developed using our VIAdel(TM) technology; the progress or success of our
research, development and clinical programs, the initiation and completion
of our clinical trials, the timing of the interim analyses and the timing
or success of our product candidates, particularly VIAject(TM) and
VIAtab(TM); our ability to secure additional patents for VIAject(TM) and
our other product candidates; our ability to protect our intellectual
property and operate our business without infringing upon the intellectual
property rights of others; our estimates of future performance; our ability
to enter into collaboration arrangements for the commercialization of our
product candidates and the success or failure of those collaborations after
consummation, if consummated; the rate and degree of market acceptance and
clinical utility of our products; our commercialization, marketing and
manufacturing capabilities and strategy; our estimates regarding
anticipated operating losses, future revenues, capital requirements and our
needs for additional financing; and other factors identified in our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The
Company disclaims any obligation to update any forward-looking statements
as a result of events occurring after the date of this press release.
|SOURCE Biodel Inc.|
Copyright©2007 PR Newswire.
All rights reserved